Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

Human immunodeficiency virus type 1 (HIV-1)-specific pyridinone reverse transcriptase (RT) inhibitors prevent HIV-1 replication in cell culture (M. E. Goldman, J. H. Nunberg, J. A. O'Brien, J.C. Quintero, W. A. Schleif, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern, Proc. Natl. Acad. Sci. USA 88:6863-6867, 1991). In contrast to nucleoside analog inhibitors, such as AZT, which need to be converted to triphosphates by host cells, these compounds act directly to inhibit RT via a mechanism which is noncompetitive with respect to deoxynucleoside triphosphates. As one approach to define the mechanism of action of pyridinone inhibitors, we isolated resistant mutants of HIV-1 in cell culture. Serial passage in the presence of inhibitor yielded virus which was 1,000-fold resistant to compounds of this class. Bacterially expressed RTs molecularly cloned from resistant viruses were also resistant. The resistant RT genes encoded two amino acid changes, K-103 to N and Y-181 to C, each of which contributed partial resistance. The mutation at amino acid 181 lies adjacent to the conserved YG/MDD motif found in most DNA and RNA polymerases. The mutation at amino acid 103 lies within a region of RT which may be involved in PPi binding. The resistant viruses, although sensitive to nucleoside analogs, were cross-resistant to the structurally unrelated RT inhibitors TIBO R82150 (R. Pauwels, K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykanti, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen, Nature [London] 343:470-474, 1990) and BI-RG-587 (V. J. Merluzzi, K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan, Science 250:1411-1413, 1990). Thus, these nonnucleoside analog inhibitors may share a common binding site on RT and may all make up a single pharmacologic class of RT inhibitor. This observation may have important implications for the clinical development of these compounds.

[1]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  S. Goff,et al.  Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the DNA polymerase and RNase H activities. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Hughes,et al.  Effects of small insertions on the RNA-dependent DNA polymerase activity of HIV-1 reverse transcriptase. , 1989, Virology.

[5]  M. A. McClure,et al.  Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Gilcher.  Human retroviruses and AIDS. , 1988, The Journal of the Oklahoma State Medical Association.

[7]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[8]  A. Fauci,et al.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. , 1988, Science.

[9]  W. Schleif,et al.  Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site. , 1990, Molecular pharmacology.

[10]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[11]  L. Jagodzinski,et al.  Complete nucleotide sequences of functional clones of the AIDS virus. , 1987, AIDS research and human retroviruses.

[12]  B. Larder,et al.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Y. Ohtsuki,et al.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells , 1981, Nature.

[14]  W. Schleif,et al.  Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[16]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[17]  J. Nunberg,et al.  Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins , 1990, Journal of virology.

[18]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[19]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[20]  J. Maizel,et al.  HIV-1 reverse transcriptase: structure predictions for the polymerase domain. , 1990, AIDS research and human retroviruses.

[21]  B. Chesebro,et al.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity , 1988, Journal of virology.

[22]  Hamilton O. Smith,et al.  Finding sequence motifs in groups of functionally related proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. A. Hagan,et al.  Detection , Isolation , and Continuous Production of Cytopathic Retroviruses ( HTLV-III ) from Patients with AIDS and Pre-AIDS , 2022 .

[24]  S. Goff,et al.  Expression of enzymatically active reverse transcriptase in Escherichia coli. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Pedersen,et al.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine , 1991, Journal of virology.

[26]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[27]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[28]  Brendan A. Larder,et al.  Site-specific mutagenesis of AIDS virus reverse transcriptase , 1987, Nature.

[29]  P Argos,et al.  A sequence motif in many polymerases. , 1988, Nucleic acids research.

[30]  Edwin Armstrong,et al.  COLUMBIA UNIVERSITY. , 1901, Science.

[31]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[32]  D. Richman,et al.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[33]  F. Balis,et al.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[34]  J. Pagano,et al.  Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine , 1987, Journal of virology.

[35]  S. Goff,et al.  Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase. , 1988, DNA.